Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One Interpreting Sequencing Data for Fox Chase Cancer Center

NEW YORK (GenomeWeb News) – Molecular data interpretation firm N-of-One today announced a deal with Fox Chase Cancer Center to provide interpretation and treatment strategy services for genome sequencing and testing.

Under the terms of the deal, N-of-One will analyze the molecular profiles and mutations identified in patients' cancers and provide treatment strategy profiles, including data on approved and investigational therapies, to Fox Chase physicians.

Based in Waltham, Mass., N-of-One interprets molecular data of patients with cancers and reports them to clinicians so that they can tailor treatments. Its lead technology is called PrecisionWorks. Because the technology can incorporate data from any sequencing platform, diagnostic, or bioinformatics system, N-of-One said, the technology can be easily integrated with Fox Chase's CancerCode-45 testing.

Fox Chase launched CancerCode-45 last month. It offers targeted sequencing using an adaptation of Life Technologies' Ion Torrent AmpliSeq Cancer Panel, as GenomeWeb Daily News' sister publication, Clinical Sequencing News, has reported.

"We believe that providing access to the latest data-driven knowledge and resources from the cancer field enables oncologists and cancer centers to be leaders in a competitive health care environment, assuring their patients that they are getting the best care possible," Jennifer Levin Carter, founder and chief medical officer of N-of-One, said in a statement.

Financial and other terms of the deal were not disclosed.

N-of-One and Foundation Medicine inked a deal last year to translate sequencing data into clinically relevant information.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.